E2814, which recognizes an epitope in the microtubule‐binding domain near the mid‐domain of tau, and Lu AF87908, which targets pSer396 and pSer404, are still at early phases of development to assess their safety in healthy participants and those with MCI and mild AD. Here, MAPT is linked to Alzheimer disease.